Indivior /£INDV
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Indivior
Indivior PLC, listed under the ticker symbol INDV, is a global pharmaceutical company. Founded in 2014, it primarily focuses on developing medications for the treatment of addiction and serious mental illnesses. The company operates in the pharmaceuticals sector, providing innovative treatment solutions globally.
Ticker
£INDV
Sector
Primary listing
LSE
Industry
Pharmaceuticals
Headquarters
Employees
1,041
ISIN
GB00BN4HT335
Website
Indivior Metrics
BasicAdvanced
£1.3B
-
-£0.36
0.34
-
Price and volume
Market cap
£1.3B
Beta
0.34
52-week high
£13.49
52-week low
£5.55
Average daily volume
335K
Financial strength
Current ratio
0.879
Quick ratio
0.642
Long term debt to equity
-119.649
Total debt to equity
-129.825
Interest coverage (TTM)
8.38%
Profitability
EBITDA (TTM)
228.898
Gross margin (TTM)
81.62%
Net profit margin (TTM)
-5.30%
Operating margin (TTM)
24.36%
Effective tax rate (TTM)
-8.77%
Revenue per employee (TTM)
£829,660
Management effectiveness
Return on assets (TTM)
12.60%
Return on equity (TTM)
45.09%
Valuation
Price to revenue (TTM)
1.534
Price to book
-4.5
Price to tangible book (TTM)
-4.4
Price to free cash flow (TTM)
17.593
Free cash flow yield (TTM)
5.68%
Free cash flow per share (TTM)
58.43%
Growth
Revenue change (TTM)
4.09%
Earnings per share change (TTM)
-1,489.27%
3-year revenue growth (CAGR)
12.67%
10-year revenue growth (CAGR)
0.76%
3-year earnings per share growth (CAGR)
-24.72%
10-year earnings per share growth (CAGR)
-15.26%
What the Analysts think about Indivior
Analyst ratings (Buy, Hold, Sell) for Indivior stock.
Bulls say / Bears say
Piper Sandler maintains an Overweight rating on Indivior, citing long-term growth potential for Sublocade, despite near-term challenges. (Investing.com)
Indivior's strong Q2 performance, with a 24% increase in Sublocade sales and a healthy cash position, prompts a Buy rating from analysts. (Markets Insider)
Deutsche Bank reiterates a Buy rating for Indivior, highlighting the company's positive outlook and growth trajectory. (Markets Insider)
Indivior faces a shareholder lawsuit alleging overstated financial prospects for products like Sublocade, leading to a significant stock price decline. (Bloomberg Law)
The company announced the cessation of sales and marketing for its schizophrenia treatment, PERSERIS, and reduced its 2024 revenue guidance, resulting in a 33.6% stock price drop. (Morningstar)
Indivior's stock hit a 52-week low of $7.84 amid market challenges, reflecting significant investor concerns over competitive pressures and legal issues. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Indivior Financial Performance
Revenues and expenses
Indivior Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Indivior stock?
Indivior (INDV) has a market cap of £1.3B as of June 20, 2025.
What is the P/E ratio for Indivior stock?
The price to earnings (P/E) ratio for Indivior (INDV) stock is 0 as of June 20, 2025.
Does Indivior stock pay dividends?
No, Indivior (INDV) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Indivior dividend payment date?
Indivior (INDV) stock does not pay dividends to its shareholders.
What is the beta indicator for Indivior ?
Indivior (INDV) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.